Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (1808)	3/4/1999 10:08:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 2135

I also have no current position in ENMD, although I have had profitable rides on both the long and short sides. There is no way that anyone with the slightest understanding of biotech could interpret the ENMD announcement for anything other than what it was - a contract to have Covance attempt to manufacture the drug (by a different process than BMY had been trying). Covance is a respected contract manufacturer, but is not a partner in the venture as was BMY, and was not characterized as such in the announcement. I would characterize your "recommendation" as more manipulative than anything in the ENMD announcement. Peter